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doi:10.1Introduction: Platelet adhesion and activation are a significant source of clinical complications. Preventing for-
eign surface–platelet interaction may improve biocompatibility of implantable medical devices. This study eval-
uated efficacy of novel technique for electrically modifying surface of conductive biomaterial and attaching
blood components to prevent thrombogenesis. Specifically, this new surface modification technology, Forcefield
(ATS Medical, Inc, Minneapolis, Minn), was designed to prevent platelet adhesion on pyrolytic carbon. A mod-
ulated low-voltage current is directly applied to pyrolytic carbon surfaces to stimulate adherence of a layer of
charged proteins from circulating blood components that is resistive to platelet deposition.
Methods: Feasibility of Forcefield technology was tested in line with cardiopulmonary bypass circuit in patients
undergoing standard cardiac surgery (n ¼ 6). Forcefield treatment was applied to segment of pyrolytic carbon
with 15 minutes (n¼ 3) and 30 minutes (n¼ 3) of electrically stimulated exposure time, and resulting segments
were compared with untreated pyrolytic carbon segment. Platelet adhesion confluence was then quantified by
scanning electron microscopy.
Results: Confluence of the Forcefield-treated pyrolytic carbon segments (3.3%  2.2%) was significantly
reduced relative to untreated pyrolytic carbon control segments (81.7%  24%, P< .001). There were no
discernible differences in cell confluence with Forcefield-treated segments as function of exposure time (15
or 30 minutes).
Conclusions: Forcefield technology may enable modification of pyrolytic carbon surfaces to prevent platelet
adhesion and thrombogenesis of implanted medical devices, including heart valves, stents, catheters, and ven-
tricular assist devices, and may eliminate the need for anticoagulant and antiplatelet therapies. (J Thorac Car-
diovasc Surg 2011;142:921-5)Biocompatibility of implantable medical devices has long
been a concern for clinicians because of the morbidity asso-
ciated with their use. This is especially true for those bioma-
terials in contact with blood, such as artificial heart valves,
which currently carry a significant risk of thromboembolic
events. Pyrolytic carbon (PYC) has been one of themost suc-
cessful and widely used biomaterials by the medical device
industry. PYC is considered an excellent biomaterial for use
in medical devices ever since its original creation for use in
nuclear reactors.1 Today, PYC remains themost popular bio-
material for implanted medical devices, as evidenced by its
use in more than 4million heart valves produced annually in
more than 25 different design configurations. Despite thee Division of Thoracic and Cardiovascular Surgery,a Department of Surgery,
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Sprevalence of PYC use, the requirement for chronic antico-
agulation therapy remains a significant lifetime risk factor.
Warfarin is generally administered and often supplemented
with aspirin or dipyridamole to inhibit platelet activation,
which is a contraindication for those patientswho cannot tol-
erate long-term anticoagulation treatment.2
Ideally, biomaterial surfaces would have hydrophobic and
hydrophilic properties, thereby attracting specific proteins to
increase biocompatibility while repelling other blood com-
ponents to prevent adhesion.Blood components such as albu-
min, the most abundant protein present in blood plasma,
possess ‘‘passive’’ antithrombogenic and antibacterial prop-
erties.3,4 It has been reported that albumin is rapidly absorbed
into the PYC biomaterial and that it inhibits platelet
adhesion.5-7 Conversely, recent studies indicated a greater
activation of platelets by exposure to PYC.8,9 To overcome
the limitations of untreated PYC and take advantage of its
potential antithrombogenic properties when albumin has
been surface-bound,ATSMedical has developed a novel sur-
face modification technique that results in a molecular layer
of charged proteins and lipids bound to the surface of the
PYC patented as Forcefield technology (ATS Medical, Inc,
Minneapolis, Minn). In the Forcefield application process,
a modulated low-voltage signal is applied directly to the
PYC material while it is in contact with circulating blood.rdiovascular Surgery c Volume 142, Number 4 921
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
PYC ¼ pyrolytic carbon




SIt is hypothesized that this process of electrically stimulating
the PYC surface will attract blood proteins and lipids to cre-
ate a platelet-passive surface, producing an antithrombo-
genic layer. To test this hypothesis, Forcefield-treated PYC
tubular segments were tested in a cardiopulmonary bypass
(CPB) circuit during an arrested cardiovascular procedure.MATERIALS AND METHODS
Patients
A single-center pilot study of the Forcefield technology was completed
with 6 subjects (6 men; mean age, 65 years) who were undergoing elective
coronary artery bypass grafting and required CPB support. None of the pa-
tients had any preoperative hematologic comorbidities, and their renal, he-
patic, pulmonary, and neurologic functions were normal. All patients had
preoperative platelet counts within the reference range (181.2 3 106
mean count).The institutional review board of Advocate Christ Medical
Center (Oak Lawn, Ill) approved the research protocol, and informed
consent was obtained from each patient before surgery.
Design
Untreated (control) and Forcefield-activated (treatment) segments of
PYC (3.1 cm length, 1.0 cm inner diameter) were tested simultaneously.
The sterilized test section was integrated in line with the CPB circuit prox-
imal to the oxygenator, filtration system, and arterial return, which enabled
the perfusionist to direct blood flow through the test section by closing or
opening tubing clamps upstream and downstream of the test section
(Figure 1). The electrical current used to generate the Forcefield was ap-
plied to the PYC test segment (treatment) by a function generator with
the positive charged electrode (red) connected to the PYC segment and
return electrode (black) connected to the titanium tube segment. The
untreated (control) PYC segment was placed between the Forcefield-
activated PYC and titanium tube segments and was unaffected by the
applied current (no charge applied or induced).
Protocol
In all 6 patients, CPB was initiated and blood cooled to 30C in prepa-
ration for coronary artery bypass grafting. After cold blood cardioplegicFIGURE 1. Forcefield test system consisted of treated test unit, which comprise
2.5 cm long; electronic circuit board and electrodes connected to oscilloscope;
922 The Journal of Thoracic and Cardiovascular Surgarrest had been achieved, an electrical current was applied to the PYC
Forcefield segment by applying an electropositive, offset-pulsed square-
wave current at 17 Hz with a duty cycle of 41.6% (25 ms on, 60 ms off).
The Forcefield treatment was applied for 15 minutes (3 patients) or 30
minutes (3 patients). The current applied to the Forcefield-treated PYC seg-
ment and titanium electrodes was quantified at the start of CPB perfusion
and continuously monitored by oscilloscope during the Forcefield activa-
tion period. The electrical current applied to the PYC test segment was dis-
continued after the allotted Forcefield treatment time (15 or 30 minutes).
CPB blood flow through the untreated (control) and Forcefield-treated
(treatment) PYC test segments continued for duration of CPB support,
with time of exposure to blood flow recorded.
Analysis
Immediately after the discontinuation of CPB, control and Forcefield-
treated PYC test segments were removed, rinsed in saline solution, and
photographed with a digital camera. Each PYC test segment was fixed in
glutaraldehyde and dehydrated in a series of alcohol baths for scanning
electron microscopic analysis. PYC test segments were then cut longitudi-
nally with a diamond saw to enable access to the interior surface. Scanning
electron microscopic photos were taken at 253, 2003, and 10003magni-
fication. Scanning electron microscopic surface photos (10003) were used
to quantify platelet–cell confluence. Adobe PhotoShop CS2 software
(Adobe Systems Incorporated, San Jose, Calif) was used to quantify the
area and percentage of cell involvement on the surface of each PYC test
segment.10 Total pixel counts were calculated with the rectangular marquee
tool. Confluence area was determined for each segment from the pixel
number of cell confluence and the pixel number of the whole segment.
The percentage surface area was calculated by dividing the confluence
pixel number by the whole area pixel count.
RESULTS
No adverse events associated with this pilot study were
observed, and there were no postoperative complications.
All 6 patients who participated in this study were dis-
charged from the hospital after a normal recovery period.
Mean CPB time was 63 minutes, with a mean aortic cross-
clamp time of 43 minutes. In 5 of the 6 patients, the lowest
temperature obtained during cardioplegic arrest was 30C.
In 1 case of total circulatory arrest, the patient was cooled
to 18C. The mean pulsed electrical current applied to the
Forcefield-treated PYC test segment was 2.6 mA, which
was unaffected by 60-Hz interference, noise, or distortion
typically associated with operating room monitoring
devices.d section of stainless steel tubing and 2 sections of pyrolytic carbon tubing,
and function generator.
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TABLE 1. Summary of experimental parameters for comparison of
untreated (control) and Forcefield-treated (test) pyrolytic carbon
segments in line with cardiopulmonary bypass circuit for 6 patients
during coronary artery bypass grafting
Patient











1 15 27 42 90 2.6
2 30 38 68 100 2.1
3 15 62 77 59 4.3
4 30 46 76 97 2.3
5 15 44 59 99 1.0
6 30 62 92 45 7.2
Total contact time of pyrolytic carbon segments with circulating blood while in line
with cardiopulmonary bypass varied patient to patient but was equivalent for control
and Forcefield-treated segments for each patient. The percentage confluences for
control and test pyrolytic carbon segments were quantified by scanning electron
microscopy. PYC, Pyrolytic carbon.
Slaughter et al Evolving Technology/Basic ScienceActivation currents, contact times between PYC test seg-
ments and CPB circuit blood flow, and confluence results
for the 6 patients are summarized in Table 1. Total contact
time between PYC test segments and CPB circuit blood
flow, which included a 15- or 30-minute Forcefield activa-
tion period, ranged from 42 to 92 minutes (average 69 
17 minutes). The platelet confluences of the PYC control
segments (81.7%  24%) were significantly greater
(P<.01) than those of the Forcefield-treated PYC segments
(3.3% 2.2%), as shown in Figure 2.There were no statis-
tically discernible differences in platelet confluence associ-
ated with Forcefield activation time.
Platelet confluence of the control (Figure 3, A) and
treated (Figure 3, B) PYC surface sections looked distinctly
different. The surface of the control section appeared to
have a white, irregular accumulation of cells, whereas the
test surface had a clean, polished appearance. The scanning
electron microscopic analysis (Figure 4) confirmed theFIGURE 2. Platelet confluences on untreated section of pyrolytic carbon (Co
Platelet confluence on control section ranged from 59% to 100% (mean 81.7%
2.2%).
The Journal of Thoracic and Cadifference. The control surface (Figure 4, A) contained
platelets throughout, whereas the treated surface
(Figure 4, B) had few areas of platelet coverage.DISCUSSION
In this acute clinical study, Forcefield definitively
inhibited platelet adhesion on treated test sections of PYC
relative to untreated control PYC sections in a CPB circuit.
These preliminary results demonstrate the potential for en-
hanced biocompatibility of Forcefield-treated PYC surfaces
by reducing platelet adhesion and subsequent potential for
thrombosis. In addition, because Forcefield treatment is
localized to the biomaterial surface, there are no systemic
alterations in the coagulation system.
Platelet confluence was notably decreased on the treated
PYC test sections relative to the untreated control PYC sec-
tions. The specific mechanisms of action are unknown and
continue to be investigated. Early in vitro results suggest
that the electrically stimulated PYC attracts inherently
charged blood components, such as albumin, fibrinogen,
and phospholipids in a rapid and complete manner to create
a platelet-passive surface, which is consistent with previous
observations.8 Other studies have shown an anticoagulant
effect of circulating albumin absorbed onto artificial sur-
faces that results from increased resistance to platelet adhe-
sion.9,11,12 Still others have shown that a pulsating electric
field can encourage platelet activation.13 With Forcefield,
the applied electric current appears to cause albumin to be
adsorbed rapidly. These formed layers may prevent subse-
quent platelet activation, adherence, and thrombosis.
The Forcefield technology has been previously tested in
vitro to determine the optimal frequency, voltage, and
current specifications for treating PYC surfaces (proprietary
information) and in vivo in acute swine model experiments
(unpublished pilot data). The PYC surfaces from these
feasibility studies were extensively analyzed by gelntrol) and treated section of pyrolytic carbon (Test) for 6 patients in study.
24%); confluence on test section ranged from 1% to 7.2% (mean 3.3%





FIGURE 3. A, Appearance of untreated section of pyrolytic carbon (control). B, Appearance of treated section of pyrolytic carbon (test).




Selectrophoresis for preliminary surface protein assay analy-
ses. These initial analyses showed a significant difference in
surface content with respect to blood components on the
Forcefield-treated, blood-perfused surfaces (Figure 5). The
preliminary results suggest a difference in surface content
with respect to the adherent blood components on the
Forcefield-treated PYC surfaces. It is therefore hypothesized
that albumin provides a stable charge on biomaterial surface,
thus preventing electric charge–related platelet interactions
as well as alteration of the fibrinogen receptors, which may
inhibit the further binding of fibrinogen to the surface.14
PYC is an electrically conductive biomaterial that is ideal
for surface charge modification and stimulation with an ex-
ternal power source. The electric current used in this study
is similar both in current density and in morphology to that
used for most implantable pulsed systems, such as standard
cardiac pacemakers. We did not observe any adverse events
in the patients participating in this study. Although we rec-
ognize the limitations of our small number of patients, we
do not believe that Forcefield treatment will be associated
with untoward effects. Important questions remain regard-
ing the application of this technology, such as whether
Forcefield treatment can be applied to other commonFIGURE 4. Scanning electron microscopy (original magnification 10003). A,
ance of treated section of pyrolytic carbon (test).
924 The Journal of Thoracic and Cardiovascular Surgimplant biomaterials, how long the antithrombotic effect
of Forcefield treatment will last, and how best to treat
surfaces of various medical devices at implantation.
Current postoperative management of mechanical pros-
thetic valves includes the use of anticoagulation and anti-
platelet therapies to minimize the risk of thrombosis and
thromboembolic sequelae. These treatment options have
risks associated with their long-term use.15 Therefore any
therapy that has the potential to reduce the need for or
amount of anticoagulation or antiplatelet therapies has
value and merits further investigation. Possible applications
for this biomaterial modification include the surfaces of
many implantable intravascular devices, such as stents, me-
chanical heart valves, and ventricular assist devices, be-
cause patients with these devices often cannot tolerate
anticoagulant and antiplatelet therapies. This technology
could also potentially improve the biocompatibility of dial-
ysis systems, oxygenators, and catheters. Although the pre-
liminary acute clinical study data are promising, the
Forcefield-treated PYC segments were exposed to blood
for less than 2 hours. Additional testing to identify protec-
tive mechanisms, evaluate long-term durability, and vali-
date efficacy are warranted.Appearance of untreated section of pyrolytic carbon (control). B, Appear-
ery c October 2011
FIGURE 5. Gel electrophoresis analyses of untreated and Forcefield-treated test sections of pyrolytic carbon after exposure to human blood. Dark bands
between 50 and 75 kD indicate presence of albumin. It is hypothesized that albumin stabilizes charges on materials, preventing electric charge–related plate-
let interactions. At 50 kD, stimulation indicates possible change in composition of fibrinogen.
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